Profile
Jan Alan Alfheim served as the Chief Executive Officer of Oncoinvent AS from 2016 to 2023.
Prior to that, he was the Chief Operations Officer of Nordic Nanovector ASA from 2014 to 2016.
He also held positions as Director of Business Development at BELLUS Health, Inc. in 2005, Director of Technology at Dyno Radnor AS, and Chief Business Officer at Weifa ASA. Additionally, he was the President of StemPath, Inc. in 2007.
Alfheim earned an MBA from McGill University in 2002 and a graduate degree from Concordia University in 1985.
Former positions of Jan Alan Alfheim
| Companies | Position | End |
|---|---|---|
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Chief Executive Officer | 2023-08-31 |
| THOR MEDICAL | Chief Operating Officer | 2015-12-31 |
StemPath, Inc.
 StemPath, Inc. Miscellaneous Commercial ServicesCommercial Services StemPath, Inc. develops therapeutic solutions that aim to modulate the body's natural regenerative capacity. | President | 2006-12-31 |
| BELLUS HEALTH | Corporate Officer/Principal | 2004-12-31 |
| Dyno Radnor AS | Chief Tech/Sci/R&D Officer | - |
Training of Jan Alan Alfheim
| McGill University | Masters Business Admin |
| Concordia University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
GE Healthcare AS
 GE Healthcare AS Medical SpecialtiesHealth Technology GE Healthcare AS markets contrast agent for x-ray, ultrasound, Magnetic Resonance Imaging, and radiopharmaceuticals for clinicians to predict, diagnose, inform, and treat diseases. The company was founded on September 07, 1981 and it is headquartered in Oslo, Norway. | Health Technology |
Weifa ASA
 Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
| Dyno Radnor AS | |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
StemPath, Inc.
StemPath, Inc. Miscellaneous Commercial ServicesCommercial Services StemPath, Inc. develops therapeutic solutions that aim to modulate the body's natural regenerative capacity. | Commercial Services |
- Stock Market
- Insiders
- Jan Alan Alfheim
